Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by C4 Therapeutics, Inc. C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 July 16, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day July 08, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors June 10, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights May 08, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 29, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum April 09, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 April 08, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 March 05, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins March 04, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights February 22, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines January 09, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals January 04, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 04, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma December 12, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) December 12, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma November 28, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment November 20, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights November 01, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple October 11, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Announces Chief Financial Officer Succession September 05, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights August 08, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 17, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer July 05, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer June 20, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC May 30, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights May 04, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days April 19, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights February 23, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics to Present at Two Virtual February 2023 Conferences February 08, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors January 30, 2023 From C4 Therapeutics, Inc. Via GlobeNewswire Tickers CCCC Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.